Summary:
Burning Mouth Syndrome (BMS) is characterized by chronic oro-facial pain in the absence of specific oral lesions & clinically apparent mucosal alterations. It is more commonly observed in middle aged patients & postmenopausal women. It often affects tongue, cheek, lip, hard & soft palate. Usually symptoms are better observed in morning, worsen during the day and typically subside at night. The condition is multifactorial origin, often idiopathic and its etiopathogenesis remain largely enigmatic. Associated medical conditions may include neurologic and metabolic disorder, gastrointestinal, urogenital as well as drug reactions. BMS are of two types, primary & secondary. Primary BMS is essential or idiopathic where secondary BMS is caused by local, systemic and/or psychological factors. Clinical diagnosis depends on the careful history taking, physical examinations and laboratory findings. Vitamin, Zinc or Hormone replacement therapy has been found to be effective with deficiency of the corresponding factors. The drug therapy with alpha-lipoic acid, capsaicin, clonazepam, benzodiazepines, tricyclic antidepressants, anticonvulsants may be effective in symptomatic treatment of BMS. But the treatment is still unsatisfactory and there is no definitive cure.

Keywords: Burning Mouth Syndrome, Glossodynia, Review, Stomatodynia

Introduction:
The international association for the study of pain (IASP) has identified BMS as a “Distinctive nosological entity” characterized by “unremitting oral burning or similar pain in the absence of detectable oral mucosa change”¹. Burning mouth syndrome is typically described by the patient as burning, stinging and/or itching of the oral cavity in the absence of any organic disease. It lasts at least for 4-6 months duration and typically located on the tongue, particularly in the tip and lateral borders, lips, hard & soft palate, alveolar ridges with the buccal mucosa and floor of the mouth being less frequently involved.²⁻⁵ BMS mainly affects middle aged or old women with hormonal changes or psychological disorders.⁶⁻⁸ BMS can be accompanied by Dysgeusia (distortion in sense of taste), Glossodynia (painful tongue), Glossopyrosis (burning tongue) & Xerostomia (dry mouth). However, careful history taking, physical examination and appropriate laboratory testing can be effective in the proper treatment planning of BMS. BMS is usually treated through a multidisciplinary approach by antidepressants, analgesics, antiepileptics, antifungals, antibacterials, sialagogues, antihistamines, anxiolytic, antipsychotics and vitamin, minerals and hormonal replacements. Moreover patients need psychological support for the long term rehabilitation.

Discussion:
Epidemiology
BMS typically observed in middle age/old women with an age range of 38-78 years.³⁻⁵,⁹⁻¹¹. The condition is extremely rare in patients under 30 years and never been reported in children and adolescence.¹² BMS has a significant female predilection with the ratio is about 7:1.¹⁸⁻¹¹,¹³ These differences between genders may be explained by biological, psychological & sociocultural factors. Prevalences of BMS reported from international studies ranges from 0.7%- 4.5%¹¹,¹⁴⁻¹⁸. Epidemiological studies revealed that this condition is more common in pre and postmenopausal women which ranges upto 12-18%.¹⁹
Recent analysis showed an increase likelihood of gastrointestinal & urogenital disease in patient with BMS. Patient with BMS had a statistically higher intake of medications for gastric disease.

Pathophysiology:
Though the pathophysiology of Burning Mouth Syndrome is not well understood, significant differences of thermal and nociception thresholds of patients with BMS are established in comparison to control subjects. Thus a neuropathic mechanism for BMS is currently favored though the controversy remains exist between peripheral and central dysfunction. Central neuropathic mechanisms have been demonstrated following thermal stimulation of the nerve in patients with BMS. Patients with BMS show patterns of cerebral activity similar to those that appear in other neuropathic pain disorders, suggesting that the cerebral hypoaactivity could be an important element in the pathogenesis of BMS.

Etiological factors
The exact etiology of BMS is unknown. Although there is no definitive cause of primary BMS, there are numerous potential secondary causes of the burning mouth syndrome. Several factors play an important role in the etiology of BMS. These are grossly classified to local, systemic and psychological factors. The contributing factors may be physical, chemical or biological (some bacteria and fungi). The important factors are:

1. Mechanical factors: Poorly fitted oral or dental prosthesis that produce microtrauma or local erythema.
2. Parafunctional Habits: Tongue thrust, Bruxism, clenching, Continual rubbing over the teeth & prosthesis, buccal, labial, lingual biting & compulsive movements of the tongue.
3. Local allergic reactions: High levels of residual monomers, nylon, ascorbic acid, cinnamon, nicotinic acid, dental materials (zinc, cobalt, mercury and palladium). Sodium laurel sulfate a detergent in toothpaste may also be involved in the development of dry mouth.
4. Nutritional abnormalities: Vitamin B1, B2, B6, B12, as well as folic acid, pernicious anemia, iron deficiency anemia, Vitamin E and Vitamin C deficiencies.
6. Hormonal change: Dryness of mucosal membrane from age related reduction in estrogen & progesterone levels & increased frequency of psychological disorders of middle aged and elderly women, uncontrolled diabetes mellitus, gastro-oesophageal reflux, thyroid dysfunction.
7. Drugs: Antihistamine, Neuroleptics, anti-hypertensives principally those act on renin angiotensin system (captopril, enalapril, lisinopril) & ACE inhibitors.
8. Psychiatric disorders: Anxiety, depression, personality disorder, cancerophobia, higher tendency to worry about health.
10. Autoimmune disease: Sjogren’s syndrome, systemic lupus erythematosus, lichen planus.
11. Others: Loss of taste buds, depapillation of tongue, oral desquamation due to agechange, side effects of radiation or chemotherapy, cranial nerve injury, parkinson’s disease, trigeminal neuralgia, glossopharyngeal neuralgia, herpes simplex, herpes zoster, smoking.
12. Idiopathic factors

Classification of BMS
According to clinical symptoms BMS is classified to primary or essential/ idiopathic and secondary.

1. Primary or essential/ idiopathic: In primary BMS organic causes cannot be identified and peripheral or central neuropathological pathways are involved.
2. Secondary BMS: Result from local or systemic pathological conditions. Causes are local infection, autoimmune diseases of the oral mucosa (lichen planus), nutritional and vitamin deficiencies, glossitis, salivary disorders, allergies, irritation caused by reflux, dental-alveolar diseases, metabolic disorders, candidiasis, nerve damage, trauma, diabetes mellitus, gastrointestinal and urogenital diseases or administration of certain drugs.
According to pain pattern BMS is classified into three types\textsuperscript{4,12,14,21,41}

1. Type-I (35%): Characterized by pain free awakening, worsening throughout the day, and receiving its peak intensity by evening. This type is usually associated with systemic disorders such as nutritional deficiencies, diabetes mellitus.

2. Type-II (55%): Characterized by continuous symptoms throughout the day but not at night. This type is usually associated with psychological disorders.

3. Type-III (10%): Characterized by intermittent symptoms with pain free episodes during the day. This type is usually associated allergic reactions.

**Clinical features**

The chief complaint of BMS patient is oral burning. The symptom is described by individual patient as continuous & chronic discomfort, sudden or intermittent onset of pain. Pain is increased progressively during the day and pain is relieved by sleeping and eating foods (although some may worsen the pain)\textsuperscript{27,39}. Patient may also describe the symptom as tingling, scalding, annoying, tender or numb filling of the oral mucosa. The pain is primarily bilateral and typically on the anterior 2/3 of the tongue (71-78%) followed by dorsal and lateral border of the tongue, anterior portion of hard palate, labial mucosa or gingiva with no identifiable precipitating factors except stress and other psychological factors\textsuperscript{14-16,42}. To fulfill the diagnostic criteria for BMS, pain episode must occur continuously at least 4-6 months\textsuperscript{1,43}. Acidic or spicy foods may increase burning symptoms\textsuperscript{44}. BMS patient may suffer from headache & TMJ pain\textsuperscript{45}. They often show easy fatiguability, sensitivity, anxiety, muscular tension and a tendency to be more concerned about their health. Sleep disturbance may also be present. 70% of BMS patient has persistent test disorders as bitter, metallic or both\textsuperscript{3,8,46-48}. Xerostomia may be the complaints of approximately 46-67% of BMS patient\textsuperscript{6,8,11}. Other symptoms include dysgeusia, sensory disturbance and sticky sensation, dysphagia, burning irritation of lingual papilla, pruritis, and intolerance to prosthesis\textsuperscript{14,17}. Oral findings are erythema, geographic tongue, candidiasis, atrophic glossitis, lichen planus\textsuperscript{49}.

**Diagnostic criteria**

Taking a thorough and comprehensive history & laboratory findings are the key to diagnosis. Diagnosis of BMS is very much difficult because BMS is positively designed only by symptoms without signs or etiologies. The symptomatic trayd rarely occurs simultaneously in one patient. Overlapping stomatitis may confuse the clinical presentation. However, some diagnostic work up include oral examination, salivary parameters, nutritional parameters, hormonal parameters, medication, parafunetional habits, contact allergies, psychological and psychosocial evaluation. There are various investigations that can be used to rule out secondary causes of BMS such as blood count which may reveal infections or anemia, blood level of iron, zinc, folic acid, vitamin B-complex, serum ferritin, fasting blood sugar, allergy testing, fungal or oral cultures, thyroid functions & serum autoantibodies\textsuperscript{4,44,50,51}

**Differential diagnosis of BMS**

The BMS diagnosis may be confusing with stomatitis, atypical facial pain, atypical odontalgia, pemphigoid, pemphigus, denture design and tooth restoration failure, herpes simplex or herpes zoster, neoplastic lesions, trauma to lingual or mandibular nerve from dental surgery.

**Treatment**

Treatment of BMS patient varies in individual patient. A multidisciplinary approach is needed for the treatment of BMS. Primarily patients need psychological support. Patient must be informed about the nature of the condition. They should assured as the syndrome is common in middle aged & elderly individual and the syndrome is not any form of cancer. They should also inform that all the symptoms may not definitely disappear. The investigator should have a detailed review of patients personal, familiar, medical and dental histories and a careful interpretation of data obtained from various physical and laboratory investigations to identify the symptoms are primary or secondary. A lack of oral mucosal pathology is mandatory for the diagnosis of BMS. As the symptoms of primary BMS are idiopathic and its etiology is unknown, a variety of drug treatment is found beneficial in some research. Some drugs are used topically and some are systemically. Behavioral interaction is needed sometimes. Medications used for BMS include antidepressants, analgesics, antiepileptics,
antifungals, antibacterials, sialagogues, antihistamines, anxiolytic, antipsychotics and vitamin, minerals and hormonal replacements. Topical application of capsaicin (0.02% cream 3-4 times daily) has been used as a desensitizing agent or analgesic for treatment of oral mucosal burning. But it is usually unaccepted by the patient due to its taste. Furthermore it causes an increase in the burning sensation at the beginning of the treatment. Another topical drugs used are lidocaine, clonazepam, benzydamine, doxepin, lectoperoxidase. Clonazepam is the only topical therapy studied in a double-blind randomized placebo controlled fashion. The topical application of clonazepam (by sucking a tablet of 1 gm) two or three times a day for 14 days treatment period provided reduced burning in two thirds of the patients studied. The most commonly used local anesthetic agent lidocaine has not been shown as an effective treatment due to their short duration of analgesic action. Topical application of Aloe vera gel (0.5 ml three times a day) combined with tongue protector found to be effective. Systemic drugs for BMS treatment include gabapentin, pregabalin, amitriptyline, nortriptyline, clonazepam, pramipexole and capsaicin. Results with gabapentin were found little or no effect on BMS treatment while positive results were obtained with pregabalin use. Systemic use of capsaicin (0.25% three times a day for one month) is found a significant reduction of pain intensity. It is not recommended for extended treatment as 32% of patients experience gastric pain after 4 weeks of treatment. Systemic use of clonazepam (0.25 mg/day increasing to a maximum of 3 mg/day) has also been found better results. Combined topical and systemic use of clonazepam has found more effective. Several studies suggest that alpha lipoic acid (200 mg three times a day) can improve the symptoms in BMS at two months. This improvement is maintained during the first year in 70% of the patient. In other studies show that the combination of psychotherapy (one hour session weekly for two months) and alpha lipoic acid (200 mg three times a day for two months) was significantly more effective than psychotherapy alone or alpha lipoic acid alone. Secondary BMS is associated with causative factors. Laboratory findings are needed to identify the cause and treatment of BMS. Deficiencies of vitamin B-complex, folic acid, iron can be treated by supplemental use of these components. For the patients with zinc deficiency, zinc replacement therapy (14.1 mg per day for 6 months) has improved the condition. The prevalence of oral discomfort is higher in perimenopausal and post-menopausal women than in premenopausal women due to estrogen deficiency.
However, hormone replacement therapy (conjugated estrogen for 21 days and medroxyprogesteron from day 12 through day 21) is effective in pain relief due to the presence of estrogen receptor on the oral mucosa. BMS patient with psychological cause is treated by psychotherapy alone or combined with drug therapy. Although, variety of drugs are used for the treatment of BMS but the treatment is not satisfactory and there is no definitive cure. It is important to inform patients about the nature of the disease to understand their pathology.

### Several drugs and therapies used for treatment of BMS

<table>
<thead>
<tr>
<th>Author, date</th>
<th>Drug or therapy used</th>
<th>comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun et al. 2013 (59)</td>
<td>Vitamin supplement treatment: Supplementation with vitamin BC capsules plus relatively high doses of corresponding deficient hematincies (vitamin B12, folic acid and iron)</td>
<td>Approximately 44.4% of 399 patients with BMS show complete remission of all oral symptoms</td>
</tr>
<tr>
<td>Cho et al. 2010 (57)</td>
<td>Zinc replacement treatment: A zinc supplement (14.1 mg/day) for 74 (26.8%) BMS patients with zinc deficiency</td>
<td>Zinc replacement therapy for 6 months can lower the mean numerical pain scale from 8.1 to 4.1 compared with a mean decrease from 7.7 to 6.7 in a control group</td>
</tr>
<tr>
<td>Forabasco et al. 1992 (58)</td>
<td>Hormone replacement treatment: 27 post-menopausal patients with oral discomfort are treated with conjugated estrogens (premarin) 0.625 mg/day for 21 days plus medroxyprogesteronacetate (follaral) 10 mg/day from day 12 through day 21 of the treatment cycle for three consecutive 21 day cycles</td>
<td>Hormone replacement therapy can relieve the symptoms and improve oral cytologic features in 15 of 27 patients with oral symptoms. The relief of oral discomfort following hormone replacement therapy is due to the presence of estrogen receptors on the oral mucosa</td>
</tr>
<tr>
<td>Epstein and Margoc. 1994 (52)</td>
<td>Topical capsaicin treatment: Capsaicin cream (0.025%) to the site of discomfort four times a day for at least 4 weeks</td>
<td>Topical capsaicin can be used as a desensitizing agent or an analgesic for treatment of oral mucosal burning</td>
</tr>
<tr>
<td>Greemeau-Richard et al. 2004 (53)</td>
<td>Topical clonazepam treatment: The patients are instructed to suck a tablet of 1 mg clonazepam with saliva at the oral pain sites for 3 mins and then to split. This protocol is repeated three times a day for 14 days</td>
<td>Clonazepam acts as an agonist of gamma-amino butyric acid (GABA) receptors. A greater reduction of pain score in clonazepam-treated patients than in placebo-treated patients suggests that the action of this drug is related to peripheral nervous system dysfunction in patients with BMS and the presence of GABA receptors in peripheral tissues</td>
</tr>
<tr>
<td>Sardella et al. 1999 (60)</td>
<td>Topical lidocaine benzylamine hydrochloride treatment: Lidocaine or 0.15% benzylamine hydrochloride as a mouthwash</td>
<td>Lidocaine is a local anesthetic agent and 0.15% benzylamine hydrochloride has anesthetic and anti-inflammatory effect. These two agents can lessen the pain and burning symptoms in patients with BMS. But the analgesic effect is of short duration.</td>
</tr>
<tr>
<td>Lopez-Jornet et al. 2012 (61)</td>
<td>Topical aloe vera treatment: Topical application of 0.5 ml aloe vera gel at 70% to the sore areas of the tongue three times a day combined with a tongue protector.</td>
<td>This agent is effective in reducing tongue burning and pain</td>
</tr>
<tr>
<td>Petruzi et al. 2004 (54)</td>
<td>Systemic capsaicin treatment: 0.25% capsaicin three times a day for 30 days</td>
<td>The drug can reduce the pain intensity. However its use is not recommended for extended treatment as 32% of patients experience gastric pain after 4 weeks of treatment.</td>
</tr>
<tr>
<td>Grushka et al. 1998 (62)</td>
<td>Systemic clonazepam treatment: 30 patients with BMS take an initial dose of 0.25 mg clonazepam daily with an increase in dose of 0.25 mg clonazepam on a weekly basis if symptoms continue</td>
<td>Approximately 70% of patients with BMS experience pain reduction with effects at low doses</td>
</tr>
<tr>
<td>Hackmann et al. 2012 (63)</td>
<td>Systemic clonazepam treatment: 0.5 mg clonazepam per day</td>
<td>The agent is effective for reducing pain and burning sensation</td>
</tr>
</tbody>
</table>

*table continued*
Conclusion:

BMS is a painful condition interfering with patient's normal livelihood. Evaluation must be focused on ruling out all secondary causes of oral burning and treating the underlying etiology. New evidence for the neuropathic basis of the syndrome is emerging. There are no well-defined data and studies to formulate a consensus on this syndrome. Therefore research in this area undertaken according to a variety of approaches is needed for a clean definition, diagnostic criteria and to establish a proper treatment planning.

References:


